dr. garassino discusses promising findings with osimertinib for patients with nsclc and brain mets
Published 7 years ago • 386 plays • Length 2:05Download video MP4
Download video MP3
Similar videos
-
1:30
dr. garassino on erlotinib/ramucirumab versus osimertinib in egfr nsclc
-
3:17
osimertinib in egfr-positive nsclc with brain metastases
-
1:34
dr. garassino on the pacific trial for nsclc
-
6:46
treatment of egfr nsclc brain metastases
-
1:36
dr. garassino discusses recent pivotal immunotherapy findings in nsclc
-
1:36
dr. garassino on increased pfs with ramucirumab combo for nsclc
-
9:49
osimertinib as frontline therapy for egfr-positive nsclc
-
1:41
dr. goldberg on resistance to osimertinib for nsclc
-
1:31
dr. gold on the future of osimertinib in lung cancer
-
5:04
shaw controlling brain metastases in patients with molecular driven adv nsclc
-
7:45
upfront use of osimertinib in egfr nsclc
-
5:45
osimertinib in t790m-mutant lung cancer
-
2:05
the impact of brain metastasis
-
6:59
gracecast - are there alternatives to radiation for patients with brain metastases
-
2:00
dr. goldberg on sequencing following treatment with osimertinib in nsclc
-
6:22
osimertinib’s role in egfr metastatic lung cancer
-
8:55
global perspectives on use of osimertinib in egfr nsclc
-
1:33
dr. yang on resistance mechanisms from osimertinib in nsclc
-
29:12
gracecast-072_lung-cancer_q&a on prevention and treatment of brain metastases